StockIQ.techExelixis, Inc. (EXEL) Stock Analysis
Free AI-powered analysis and research for Exelixis, Inc. stock
Sector: Healthcare
EXEL snapshot
Data as of 3 Nov 2026 close. Updated daily.
Exelixis, Inc. scores 100/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 99% of its 52-week range, up 91.7% over the past year. Latest reported figures show a profit margin of 35.4%, return on equity of 44.3% and revenue growth of +10.2%.
What is driving the score
- RSI Very High (86): -5
- Strong Uptrend: +12
- MACD Bullish: +8
- Excellent Profit Margin (35.4%): +10
- Low Debt (0.09 D/E): +8
- Strong Liquidity (3.21 Current Ratio): +8
- Excellent ROE (44.3%): +8
- High P/B (9.26): -5
- Strong Long-term Uptrend: +8
- Strong Rise (+91.7% over 1 year): +10
- Low Volume (0.5x): -3
- Near 52-Week High (99%): +5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full EXEL report
Exelixis, Inc. (EXEL) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze EXEL Now →📰 Latest Update
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
Mon, November 2, 2026 at 1:15 PM UTC 4 min read
Exelixis (EXEL) reported total revenue of $658.7 million for the quarter ending September 2026, reflecting a 10.2% year-over-year increase. However, international revenue showed mixed results, with Japan contributing $5.3 million, falling short of expectations, while Europe generated $44.3 million, slightly below analyst estimates. Looking ahead, analysts project total revenue for the current fiscal quarter to reach $673.39 million, with Japan and Europe expected to contribute 1.3% and 6.7%, respectively.